Health Care, News

Bionor Pharma Positioned for Execution of the Kick, the Kill and the Boost Strategy, Aiming Towards a Functional Cure for HIV

Bionor Pharma ASA (OSE: BIONOR) announced today results from the third quarter and first nine months of 2013.

The Q3 report will be presented by webcast 8 November at 8.30 am CET. Link for registration and access to the webcast: http://www.media-server.com/m/p/zovaz8yn
See further information about the webcast and call numbers below.

Download the Q3 report and Q3 presentation.

 

If you would like to find out more about Bionor Pharma, please visit their website here.


Post Views:
650
Post Views: 650

Associate Companies

Bionor Pharma Asa

Related Articles


FSV Group upgrades their ROV park according to new trends
Read more

Servogear powering innovative wind farm vessel
Read more

DNV GL approves Shell carbon capture technology to bring down emissions from Fortum waste-to-energy plant
Read more

COVID-19 dampens long-term energy demand and highlights scale of climate emergency
Read more

Sedex opens for virtual assessments after successful pilot. DNV GL approved provider
Read more

DNV GL issues provisional type certificate for GE’s Haliade-X 12 MW
Read more

DNV GL’s WindGEMINI wind turbine under-performance alert system updated
Read more
VLGC BW Leo 1 (image care of BW LPG)

Milestone for first LPG conversion with Isle of Man design acceptance
Read more

DNV GL’s My Care: Applying hospital-grade infection risk management to ships
Read more

Generosity and ingenuity help our team protect themselves and others
Read more

DNV GL wins ‘Implementation Contractor of the Year for 2020’ award by The Michigan Energy Efficiency Contractors Association
Read more

DNV GL launches new certification in infection prevention for the maritime industry
Read more
X